T. Rowe Price Associates
KRSA

T. Rowe Price Associates’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

T. Rowe Price Associates’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,116
Closed -$4.36M – 2678
2020
Q3 		$4.36M Buy
5,116
+691
+16% +$79K ﹤0.01% 1419
2020
Q2 		$3.66M Sell
4,425
-423
-9% -$35.4K ﹤0.01% 1421
2020
Q1 		$1.8M Buy
+4,848
New +$346K ﹤0.01% 1527
2019
Q4 		– Sell
-1,657
Closed -$2.81M – 2534
2019
Q3 		$2.81M Buy
1,657
+573
+53% +$124K ﹤0.01% 1489
2019
Q2 		$1.74M Buy
+1,084
New +$307K ﹤0.01% 1635

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates's KRSA Position: Q4 2020 in Review

T. Rowe Price Associates sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2020, closing a stake of 5,116 shares — an estimated $4.36M sold.

T. Rowe Price Associates first reported a position in KRSA in Q2 2019 and held it in 5 quarters. The position peaked at $4.36M in Q3 2020. 70 funds tracked by Wall St. Rank hold KRSA as of Q4 2020.

  • T. Rowe Price Associates reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 5,116 Korsana Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $4.36M.
  • T. Rowe Price Associates first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 5 quarters.
  • T. Rowe Price Associates's Korsana Biosciences, Inc. Common Stock position peaked at $4.36M in Q3 2020.
  • 70 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.